|
||
Address correspondence to Alan Aderem, Institute for Systems Biology, 1441 N. 34th St., Seattle, WA 98103. Phone: (206) 732-1203; Fax: (206) 732-1299; email: aderem{at}systemsbiology.org
| Abstract |
|---|
|
|
|---|
Key Words: innate immunity bacterial infection pathogen phagocytosis nitric oxide
| Introduction |
|---|
|
|
|---|
Macrophages play a critical role in both innate and acquired immunity because of their unique ability to internalize and degrade bacterial pathogens through the process of phagocytosis. Once internalized, the bacterium is contained in a specialized vacuole known as a phagosome. Phagosomes are dynamic organelles that mature over time through a series of fusion and fission events with vesicles of the endosome/lysosome system. Usually the terminal step in macrophage phagocytosis is the formation of a mature phagolysosome in which the bacterium is killed and processed for eventual presentation to CD4+ T cells. Although it is understood that several bacterial pathogens have evolved strategies to subvert macrophage phagosome maturation and thus evade host defense systems (10), little is known about the mechanism by which this is accomplished.
We have shown previously that a novel adaptor protein, amphiphysin IIm, is required for particle internalization during phagocytosis (11). Amphiphysin IIm binds the GTPase dynamin and recruits it to the nascent phagosome (11). Deletion of the SH3 domain of amphiphysin IIm generates a mutant protein that no longer binds dynamin, and functions as a dominant negative inhibitor of amphiphysin IIm activity (11). Thus, expression of AmphIImSH3 in macrophages prevents the internalization of large particles (>1 µm) by inhibiting membrane extension around the particle.
We report here that, although amphiphysin IIm usually trafficks off phagosomes early in their maturation (
35 min after particle binding), it is retained on the C. pneumoniae vacuole for >72 h and its function appears to be a critical factor in the survival of the bacterium.
| Materials and Methods |
|---|
|
|
|---|
The cell line RAW-TT10 is a stable line of RAW 264.7 cells that expresses the tetracycline transactivator. In all experiments in this paper, RAW-TT10 cells were transiently transfected by electroporation. All experiments were performed in the absence of tetracycline to allow for high-level expression of the transfected vectors.
Primary Cells.
Murine resident peritoneal macrophages were isolated from CD1 mice (Charles River Laboratories) and cultured as described previously (13). No antibiotics were added to any of the media used in the experiments described in this paper. Bone marrow macrophages were also obtained from CD1 mice. Bone marrow cells were obtained from femurs, plated in Petri dishes in RPMI 1640 with 10% FCS and 20% L-cell media and cultured for 5 d. The macrophages were transferred to glass coverslips and used the next day for experiments.
Bacterial Culture and Infection.
C. pneumoniae (strain AR-39) was cultured in HL cells and purified by density gradient centrifugation (Hypaque-76; Winthrop-Breon Laboratories; reference 14). The purified organisms were resuspended in sucrose phosphate glutamic acid and frozen at 70°C until use. Infectivity was determined by direct fluorescent staining of chlamydial inclusions using the FITC-conjugated Chlamydia genus-specific Mab, CF-2 (15). To determine the viability and growth of C. pneumoniae in macrophages, the macrophages were infected at a multiplicity of infection (MOI) of 10:1, the cells were harvested 3 d after the infection and sonicated, and the infectivity titers were assayed in HL cells. Cells were analyzed with confocal microscopy. Inclusions were counted in 25 high-power from three coverslips for each experiment. Data shown represent the average from at least three separate experiments.
The viability of the macrophages before infection was determined by sorting a known number of cells expressing either p-TIGZ2 or pTIGZ2-AmphIImSH3 into 96-well plates. These cells were lifted, and viable cell number was determined by counting cells in the presence of trypan blue. The values expressed are corrected for input cell number.
Immunofluorescence, FACS, and Nitric Oxide (NO) Measurement.
The antiamphiphysin IIm antibody, M8D10, was generated and characterized as described previously (13). M8D10 was detected with either FITC or Texas red antirat IgG secondary antibody (Cappel and ICN Biomedicals). Immunofluorescence and FACS staining was performed as described previously (11, 12). Lysine fixable dextran, which has a molecular weight of 10,000, conjugated to Alexa-Fluor 568 (Molecular Probes) was added to macrophages at a concentration of 500 µg/ml for 2 h, the cells were washed, and the dextran was chased into the macrophage lysosomes for 24 h before particle loading or infections. Zymosan, Staphylococcus aureus, and Escherichia coli were all labeled with FITC before infections.
Nitrite concentration was measured in supernatant from macrophage cultures using the Griess reagent (Molecular Probes).
Phagocytosis Assays.
Full details of the FACS phagocytosis assay and the immunofluorescence procedure have been described previously (12). In this work, 18 h after transfection, RAW-TT10 cells were incubated with the indicated particles (polystyrene "pink" particles; Spherotech, Inc.) for 10 min. The particles were washed off with PBS, and the cells were fixed and analyzed by flow cytometry.
Microscopy was used to confirm that the uninternalized particles were indeed being removed before analysis. RAW-TT10 macrophages were transfected, plated on glass coverslips and, after 18 h, were incubated with biotin-coated polysterene "pink" fluorescent beads (Spherotech, Inc.). The cells were washed and fixed with formalin. The uninternalized beads were stained with streptavidin conjugated to Cy5 (The Jackson Laboratory). Cells were analyzed on a confocal microscope (Leica).
For the C. pneumoniae internalization assay, RAW-TT10 cells were transfected with the indicated construct. 18 h later, high-expressing cells were sorted onto coverslips using a FACStarPLUS. The cells were allowed to recover for 24 h, were infected with C. pneumoniae at an MOI of 10:1 for 1 h at 37°. Uninternalized bacteria were removed by incubating the cells in trypsin/EDTA for 10 min at 37°. The cells were fixed with formalin, permeabilized with 0.25% Triton X-100 in PBS, incubated with primary antibody (CF2 antibody) and with the secondary antibody (antimouse TxR; Cappel and ICN Biomedicals), and analyzed by FACS.
Transmission Electron Microscopy.
18 h after transfection, cells expressing high levels of the indicated vectors were sorted into tissue culture dishes using a FACStarPLUS. The cells were infected for 72 h, fixed with 3% glutaraldehyde (in a 0.1-M cacodylate and 0.1-M sucrose buffer) for 1 h, and rinsed with the cacodylate buffer. Cells were post-fixed for 1 h in 1% OsO4 and dehydrated through a graded ethanol series. They were infiltrated with epoxy resin, polymerized, and cut into 80-nM sections. These were post-stained with 3% urnanyl acetate and lead citrate and examined on a Jeol 1200 ExII transmission electron microscope.
| Results |
|---|
|
|
|---|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Amphiphysin has numerous roles in membrane trafficking. Initially, it was shown to be critical in receptor mediated endocytosis; the NH2-terminal domain of amphiphysin interacts with clathrin, whereas its COOH-terminal SH3 domain interacts with the proline-rich domain of dynamin (19, 20). This results in the targeting of dynamin to forming endosomes, which is necessary for scission of the endosome from the plasma membrane (21). More recent work has demonstrated that amphiphysin also has roles in exocytosis (22, 23) and intracellular vesicular trafficking (24). Amphiphysin also appears to have a direct effect on membrane deformation and curvature (25, 26). In addition to its general role in regulating membrane traffic, we and others have also demonstrated that amphiphysin has a role in phagosome maturation by controlling membrane insertion into the forming phagosome (11, 27). This function of the molecule appears to be related to its capacity to activate dynamin and recruit PI-3 kinase (11). In turn, PI-3 kinase has a central role in regulating membrane traffic (28). Thus the role for amphiphysin in membrane traffic is unequivocal, and it is reasonable to postulate that its capture on the immature phagosome is the underlying reason why the chlamydial vacuole does not progress to a fully fledged phagolysosome where effective killing of the bacterium can occur.
It has been demonstrated recently that a related Chlamydia species, Chlamydia trachomatis, is able to survive in macrophages and that this was reversed by the activation of phospholipase D (29). Amphiphysin is known to bind directly to phospholipase D and inhibit its activity by doing so (30); it is possible that by retaining amphiphysin on its vacuole, C. pneumoniae may inhibit phospholipase D activity and promote its own survival.
The precise mechanism by which amphiphysin prevents chlamydial killing is not fully elucidated, but it does appear to involve the induction of inducible NO synthase. Macrophage production of NO is known to play a key role in host defense against a wide variety of pathogens including Mycobacterium tuberculosis, Leishmania major, Listeria monoctogenes, and Toxoplasma gondii (31). NO also has an important role in control of C. pneumoniae infection as evidenced by the observation that inducible NO synthase/ mice have increased susceptibility to respiratory infection with these bacteria (32), and are more susceptible to C. pneumoniae induced exacerbation of atherosclerotic lesions (33).
We demonstrate here that macrophages produce very little NO when they internalize C. pneumoniae. However, when amphiphysin function is abrogated, C. pneumoniae provokes robust NO production and this correlates with sterilization of the vacuole. C. pneumoniae does not globally disable the machinery necessary for NO production, as infected macrophages are still able to produce NO when exposed to a second stimulus.
Together, our data suggest that by retaining functional amphiphysin IIm on the vacuole, C. pneumoniae are able to prevent vacuole maturation, thereby avoiding the detection mechanisms that activate NO production.
| Acknowledgments |
|---|
The authors have no conflicting financial interests.
Submitted: 22 March 2004
Accepted: 13 July 2004
| References |
|---|
|
|
|---|
1 Kuo, C.C., L.A. Jackson, L.A. Campbell, and J.T. Grayston. 1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451461.[Abstract]
2 Thom, D.H., J.T. Grayston, D.S. Siscovick, S.P. Wang, N.S. Weiss, and J.R. Daling. 1992. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 268:6872.
3 Muhlestein, J.B., E.H. Hammond, J.F. Carlquist, E. Radicke, M.J. Thomson, L.A. Karagounis, M.L. Woods, and J.L. Anderson. 1996. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 27:15551561.[Abstract]
4 Muhlestein, J.B., J.L. Anderson, E.H. Hammond, L. Zhao, S. Trehan, E.P. Schwobe, and J.F. Carlquist. 1998. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:633636.
5 von, H.L. 2002. Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur. Respir. J. 19:546556.
6 Gencay, M., J.J. Rudiger, M. Tamm, M. Soler, A.P. Perruchoud, and M. Roth. 2001. Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. Am. J. Respir. Crit. Care Med. 163:10971100.
7 Villareal, C., J.A. Whittum-Hudson, and A.P. Hudson. 2002. Persistent Chlamydiae and chronic arthritis. Arthritis Res. 4:59.[Medline]
8 Hannu, T., M. Puolakkainen, and M. Leirisalo-Repo. 1999. Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford). 38:411414.
9 Balin, B.J., H.C. Gerard, E.J. Arking, D.M. Appelt, P.J. Branigan, J.T. Abrams, J.A. Whittum-Hudson, and A.P. Hudson. 1998. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med. Microbiol. Immunol. (Berl.). 187:2342.[CrossRef][Medline]
10 Sinai, A.P., and K.A. Joiner. 1997. Safe haven: the cell biology of nonfusogenic pathogen vacuoles. Annu. Rev. Microbiol. 51:415462.[CrossRef][Medline]
11 Gold, E.S., N.S. Morrissette, D.M. Underhill, J. Guo, M. Bassetti, and A. Aderem. 2000. Amphiphysin IIm, a novel amphiphysin II isoform, is required for macrophage phagocytosis. Immunity. 12:285292.[CrossRef][Medline]
12 Gold, E.S., D.M. Underhill, N.S. Morrissette, J. Guo, M.A. McNiven, and A. Aderem. 1999. Dynamin 2 is required for phagocytosis in macrophages. J. Exp. Med. 190:18.
13 Morrissette, N.S., E.S. Gold, J. Guo, J.A. Hamerman, A. Ozinsky, V. Bedian, and A.A. Aderem. 1999. Isolation and characterization of monoclonal antibodies directed against novel components of macrophage phagosomes. J. Cell Sci. 112:47054713.[Abstract]
14 Kuo, C.C., and J.T. Grayston. 1990. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 162:755758.[Medline]
15 Kuo, C.C., H.H. Chen, S.P. Wang, and J.T. Grayston. 1986. Identification of a new group of Chlamydia psittaci strains called TWAR. J. Clin. Microbiol. 24:10341037.
16 Godzik, K.L., E.R. O'Brien, S.K. Wang, and C.C. Kuo. 1995. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 33:24112414.[Abstract]
17 Underhill, D.M., A. Ozinsky, A.M. Hajjar, A. Stevens, C.B. Wilson, M. Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 401:811815.[CrossRef][Medline]
18 Cox, D., C.C. Tseng, G. Bjekic, and S. Greenberg. 1999. A requirement for phosphatidylinositol 3-kinase in pseudopod extension. J. Biol. Chem. 274:12401247.
19 David, C., P.S. McPherson, O. Mundigl, and P. de Camilli. 1996. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc. Natl. Acad. Sci. USA. 93:331335.
20 McMahon, H.T., P. Wigge, and C. Smith. 1997. Clathrin interacts specifically with amphiphysin and is displaced by dynamin. FEBS Lett. 413:319322.[CrossRef][Medline]
21 Schmid, S.L., M.A. McNiven, and P. DeCamilli. 1998. Dynamin and its partners: a progress report. Curr. Opin. Cell Biol. 10:504512.[CrossRef][Medline]
22 Sarret, P., M.J. Esdaile, P.S. McPherson, A. Schonbrunn, H.J. Kreienkamp, and A. Beaudet. 2003. Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells. J. Biol. Chem. 279:80298037.
23 Mathew, D., A. Popescu, and V. Budnik. 2003. Drosophila amphiphysin functions during synaptic Fasciclin II membrane cycling. J. Neurosci. 23:1071010716.
24 Leprince, C., E. Le Scolan, B. Meunier, V. Fraisier, N. Brandon, J. De Gunzburg, and J. Camonis. 2003. Sorting nexin 4 and amphiphysin 2, a new partnership between endocytosis and intracellular trafficking. J. Cell Sci. 116:19371948.
25 Peter, B.J., H.M. Kent, I.G. Mills, Y. Vallis, P.J. Butler, P.R. Evans, and H.T. McMahon. 2004. BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. Science. 303:495499.
26 Lee, E., M. Marcucci, L. Daniell, M. Pypaert, O.A. Weisz, G.C. Ochoa, K. Farsad, M.R. Wenk, and P. De Camilli. 2002. Amphiphysin 2 (Bin1) and T-tubule biogenesis in muscle. Science. 297:11931196.
27 Di, A., D.J. Nelson, V. Bindokas, M.E. Brown, F. Libunao, and H.C. Palfrey. 2003. Dynamin regulates focal exocytosis in phagocytosing macrophages. Mol. Biol. Cell. 14:20162028.
28 Rameh, L.E., and L.C. Cantley. 1999. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 274:83478350.
29 Coutinho-Silva, R., L. Stahl, M.N. Raymond, T. Jungas, P. Verbeke, G. Burnstock, T. Darville, and D.M. Ojcius. 2003. Inhibition of chlamydial infectious activity due to P2X7R-dependent phospholipase D activation. Immunity. 19:403412.[CrossRef][Medline]
30 Lee, C., S.R. Kim, J.K. Chung, M.A. Frohman, M.W. Kilimann, and S.G. Rhee. 2000. Inhibition of phospholipase D by amphiphysins. J. Biol. Chem. 275:1875118758.
31 Nathan, C. 1997. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest. 100:24172423.[Medline]
32 Rottenberg, M.E., A.C. Gigliotti Rothfuchs, D. Gigliotti, C. Svanholm, L. Bandholtz, and H. Wigzell. 1999. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J. Immunol. 162:28292836.
33 Chesebro, B.B., E. Blessing, C.C. Kuo, M.E. Rosenfeld, M. Puolakkainen, and L.A. Campbell. 2003. Nitric oxide synthase plays a role in Chlamydia pneumoniae-induced atherosclerosis. Cardiovasc. Res. 60:170174.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|